UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Microglial Phagocytosis and Its Regulation: A Therapeutic Target in Parkinson's Disease?

Frontiers in molecular neuroscience, 2018-04, Vol.11, p.144-144

2018

Volltextzugriff (PDF)

Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease

Neurobiology of disease, 2014-11, Vol.71, p.280-291

2014

Volltextzugriff (PDF)

PPAR-γ: therapeutic prospects in Parkinson's disease

Current drug targets, 2013-06, Vol.14 (7), p.743-751

Carta, Anna R

2013

Volltextzugriff (PDF)

BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression

Journal of integrative neuroscience, 2022-08, Vol.21 (5), p.144-144

2022

Volltextzugriff (PDF)

Genetic and Molecular Regulations of Neuronal Activity

International journal of molecular sciences, 2023-11, Vol.24 (22), p.16191

2023

Volltextzugriff (PDF)

l‐DOPA‐induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?

The European journal of neuroscience, 2017-01, Vol.45 (1), p.73-91

2017

Volltextzugriff (PDF)

Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?

Frontiers in neuroscience, 2021-04, Vol.15, p.657714-657714

2021

Volltextzugriff (PDF)

Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease

Experimental neurology, 2016-12, Vol.286, p.83-92

2016

Volltextzugriff (PDF)

PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease

The European journal of neuroscience, 2009-03, Vol.29 (5), p.954-963

2009

Volltextzugriff (PDF)

Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers

International journal of molecular sciences, 2020-11, Vol.21 (22), p.8535

2020

Volltextzugriff (PDF)

Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model

Journal of neuroinflammation, 2019-08, Vol.16 (1), p.166-166, Article 166

2019

Volltextzugriff (PDF)

Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?

Medical hypotheses, 2020-07, Vol.140, p.109776-109776, Article 109776

2020

Volltextzugriff (PDF)

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders

Frontiers in neuroscience, 2021-03, Vol.15, p.656921

2021

Volltextzugriff (PDF)

Induction of Activity-Regulated Cytoskeleton-Associated Protein and c-Fos Expression in an Animal Model of Anorexia Nervosa

Nutrients, 2023-09, Vol.15 (17), p.3830

2023

Volltextzugriff (PDF)

Microglial phenotypes in Parkinson's disease and animal models of the disease

Progress in neurobiology, 2017-08, Vol.155, p.57-75

2017

Volltextzugriff (PDF)

Nuclear ERK1/2 signaling potentiation enhances neuroprotection and cognition via Importinα1/KPNA2

EMBO molecular medicine, 2023-11, Vol.15 (11), p.e15984-e15984

2023

Volltextzugriff (PDF)

Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinson's Disease

International journal of molecular sciences, 2020-09, Vol.21 (18), p.6745

2020

Volltextzugriff (PDF)

Adolescent stress differentially modifies dopamine and norepinephrine release in the medial prefrontal cortex of adult rats

Progress in neuro-psychopharmacology & biological psychiatry, 2024-08, Vol.134, p.111055, Article 111055

2024

Volltextzugriff (PDF)

The 6-hydroxydopamine model of Parkinson's disease

Neurotoxicity research, 2007-04, Vol.11 (3-4), p.151-167

2007

Volltextzugriff (PDF)

Do PPAR-Gamma Agonists Have a Future in Parkinson’s Disease Therapy?

Parkinson's disease, 2011-01, Vol.2011 (2011), p.601-614

2011

Volltextzugriff (PDF)

The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex

Cells (Basel, Switzerland), 2022-08, Vol.11 (17), p.2628

2022

Volltextzugriff (PDF)

Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease

Frontiers in aging neuroscience, 2020-02, Vol.12, p.31-31

2020

Volltextzugriff (PDF)

Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson’s disease

Journal of neurology, 2023-11, Vol.270 (11), p.5613-5621

2023

Volltextzugriff (PDF)

Nicotine, cocaine, amphetamine, morphine, and ethanol increase norepinephrine output in the bed nucleus of stria terminalis of freely moving rats

Addiction biology, 2021-01, Vol.26 (1), p.e12864-n/a

2021

Volltextzugriff (PDF)

Immunomodulatory drugs alleviate l‐dopa‐induced dyskinesia in a rat model of Parkinson's disease

Movement disorders, 2019-12, Vol.34 (12), p.1818-1830

2019

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(90)

Publikationsform

Artikel
(100)
Buchkapitel
(4)

Sprache

Englisch
(104)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Microglial Phagocytosis and Its Regulation: A Therapeutic Target in Parkinson's Disease?

Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease

PPAR-γ: therapeutic prospects in Parkinson's disease

BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression

Genetic and Molecular Regulations of Neuronal Activity

l‐DOPA‐induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?

Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?

Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease

PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease

Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers

Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model

Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders

Induction of Activity-Regulated Cytoskeleton-Associated Protein and c-Fos Expression in an Animal Model of Anorexia Nervosa

Microglial phenotypes in Parkinson's disease and animal models of the disease

Nuclear ERK1/2 signaling potentiation enhances neuroprotection and cognition via Importinα1/KPNA2

Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinson's Disease

Adolescent stress differentially modifies dopamine and norepinephrine release in the medial prefrontal cortex of adult rats

The 6-hydroxydopamine model of Parkinson's disease

Do PPAR-Gamma Agonists Have a Future in Parkinson’s Disease Therapy?

The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex

Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease

Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson’s disease

Nicotine, cocaine, amphetamine, morphine, and ethanol increase norepinephrine output in the bed nucleus of stria terminalis of freely moving rats

Immunomodulatory drugs alleviate l‐dopa‐induced dyskinesia in a rat model of Parkinson's disease

Suchergebnisse filtern